

Table of Contents

Section I: Patient Survival

- I.1 Incident Patient Counts: ESRD Patients  
*by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.2 One-year Survival Probabilities: Incident ESRD Patients  
*From Day 91 to One year + 90 Days by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.3 Two-year Survival Probabilities: Incident ESRD Patients  
*From Day 91 to Two Years + 90 Days, by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.4 Five-year Survival Probabilities: Incident ESRD Patients  
*From Day 91 to Five Years + 90 Days, by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.5 Ten-year Survival Probabilities: Incident ESRD Patients  
*From Day 91 to Ten Years + 90 Days, by Age, Gender, Race, & Primary Diagnosis*
- I.6 Incident Patient Counts: ESRD Patients Aged 65 & Over  
*Patients Aged 65 & Over on Day 1, by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.7 One-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over  
*From Day 1 to One year, by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.8 Two-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over  
*From Day 1 to Two Years, by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.9 Five-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over  
*From Day 1 to Five Years, by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.10 Ten-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over  
*From Day 1 to Ten Years, by Age, Gender, Race, & Primary Diagnosis*
- I.11 Incident Patient Counts: Dialysis Patients  
*Dialysis Patients alive on Day 91, by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.12 One-year Survival Probabilities: Incident Dialysis Patients  
*Censored at Transplant, From Day 91 to One year + 90 Days, by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.13 Two-year Survival Probabilities: Incident Dialysis Patients  
*Censored at Transplant, From Day 91 to Two Years + 90 Days, by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.14 Five-year Survival Probabilities: Incident Dialysis Patients  
*Censored at Transplant, From Day 91 to Five Years + 90 Days, by Age, Gender, Race, Ethnicity, & Primary Diagnosis*
- I.15 Ten-year Survival Probabilities: Incident Dialysis Patients  
*Censored at Transplant, From Day 91 to Ten Years + 90 Days, by Age, Gender, Race, & Primary Diagnosis*

**Table I.1**  
**Incident Patient Counts: ESRD Patients**  
*by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	37	60	89	97	96	113	107	104	112	120	96	125	115	118	92	116	128	106	92	89	123
5-9	82	83	97	87	95	94	106	95	81	99	116	108	91	94	122	101	96	79	82	95	86
10-14	154	173	201	186	209	186	186	190	179	167	185	206	195	193	204	210	204	188	177	176	190
15-19	388	444	421	409	384	387	403	428	420	462	424	402	432	422	417	443	430	350	378	394	356
20-29	1,382	1,575	1,764	1,697	1,814	1,878	1,937	1,923	2,028	2,179	2,212	2,228	2,295	2,259	2,202	2,136	2,094	1,952	1,989	1,859	1,915
30-39	2,017	2,352	2,580	2,651	2,821	3,017	3,337	3,338	3,675	4,030	4,160	4,374	4,646	4,541	4,679	4,688	4,483	4,218	4,229	4,295	4,146
40-49	2,242	2,567	2,683	2,990	3,107	3,397	3,649	4,042	4,386	5,025	5,386	6,092	6,507	6,640	7,011	7,490	7,616	7,347	7,882	7,886	8,085
50-59	3,414	4,047	4,347	4,461	4,699	4,998	5,248	5,616	6,278	6,759	7,234	7,814	8,665	8,791	9,929	10,137	10,221	10,934	11,692	12,405	12,757
60-64	1,902	2,178	2,459	2,885	3,174	3,487	3,624	4,073	4,431	4,821	5,148	5,744	6,041	6,140	6,525	6,864	6,932	7,079	7,462	7,633	7,862
65-69	1,936	1,962	2,260	3,043	3,083	3,511	4,022	4,580	5,085	5,892	6,535	7,297	7,833	8,144	8,800	8,680	9,382	9,668	9,915	10,024	10,031
70-79	2,142	2,303	2,882	4,146	4,268	4,959	5,714	6,522	7,186	8,536	9,519	11,240	12,513	13,094	14,737	14,982	16,791	17,863	18,923	20,105	20,453
80+	358	377	539	847	910	1,133	1,379	1,614	1,951	2,403	2,794	3,265	3,816	4,121	4,674	5,036	5,986	6,774	7,471	8,383	9,039
Male	8,960	10,014	11,189	12,906	13,613	14,768	16,236	17,606	19,308	21,963	23,676	26,215	28,184	29,184	31,528	32,330	34,593	35,597	37,601	39,521	40,445
Female	7,094	8,107	9,133	10,593	11,047	12,392	13,476	14,919	16,504	18,530	20,133	22,680	24,965	25,373	27,864	28,553	29,770	30,961	32,691	33,823	34,598
White	9,929	11,536	13,717	15,430	16,267	17,935	19,608	21,200	23,209	26,293	28,566	31,758	34,284	34,529	37,895	38,077	40,108	42,740	44,727	47,495	49,006
Black	5,493	5,877	5,995	7,214	7,345	8,057	8,711	9,726	10,889	12,682	13,457	15,099	16,527	17,465	18,445	18,801	19,755	19,899	21,120	21,435	21,439
Other race	632	708	610	855	1,048	1,168	1,393	1,599	1,714	1,518	1,786	2,038	2,338	2,563	3,052	4,005	4,500	3,919	4,445	4,414	4,598
†Hispanic																7,278	7,130	7,884	8,211	8,737	
†Non-Hispanic																57,085	59,428	62,408	65,133	66,306	
Diabetes	2,133	3,413	4,728	5,502	6,684	7,718	8,921	9,959	11,220	13,634	15,317	17,845	19,811	19,586	22,771	25,080	28,184	29,802	31,784	33,263	34,576
Hypertension	2,404	3,778	5,059	5,501	6,174	7,075	7,710	8,745	9,885	11,690	12,614	14,283	15,932	15,205	17,336	15,597	16,846	17,771	18,772	19,722	20,020
Glomerulonephritis	2,059	2,955	3,704	3,892	4,125	4,323	4,432	4,696	4,999	5,341	5,610	5,920	6,151	5,997	6,424	6,589	6,935	6,656	6,696	6,622	6,423
Cystic kidney	600	823	989	1,031	1,063	1,118	1,210	1,240	1,233	1,239	1,391	1,471	1,546	1,490	1,587	1,670	1,579	1,594	1,686	1,735	1,710
Other urologic	250	366	390	457	458	588	592	602	654	717	753	1,028	1,065	937	977	1,106	1,338	1,225	1,249	1,336	1,287
Other cause	1,502	2,136	2,896	3,262	3,491	3,820	3,905	4,028	4,066	4,494	4,377	4,584	4,830	4,740	5,164	6,260	6,501	6,658	7,022	7,287	7,595
Unknown cause	1,263	1,455	1,252	1,240	1,289	1,288	1,518	1,765	1,747	1,600	1,694	2,036	2,215	1,983	2,040	2,056	2,332	2,409	2,652	2,641	2,878
Missing cause	5,843	3,195	1,304	2,614	1,376	1,230	1,424	1,490	2,008	1,778	2,053	1,728	1,599	4,619	3,093	2,525	648	443	431	738	554
All	16,054	18,121	20,322	23,499	24,660	27,160	29,712	32,525	35,812	40,493	43,809	48,895	53,149	54,557	59,392	60,883	64,363	66,558	70,292	73,344	75,043

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.





**Table I.4**  
**Five-year Survival Probabilities: Incident ESRD Patients**  
*from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

<b>UNADJUSTED</b>	<b>1980</b>	<b>1981</b>	<b>1982</b>	<b>1983</b>	<b>1984</b>	<b>1985</b>	<b>1986</b>	<b>1987</b>	<b>1988</b>	<b>1989</b>	<b>1990</b>	<b>1991</b>	<b>1992</b>	<b>1993</b>	<b>1994</b>	<b>1995</b>	<b>1996</b>
0-4	75.7	76.7	80.9	78.4	75.0	80.5	82.2	79.8	74.1	78.3	79.2	80.0	85.2	82.2	82.6	79.3	84.9
5-9	89.0	89.2	85.6	89.7	88.4	88.3	89.6	94.7	93.8	93.9	90.5	95.4	93.4	88.3	94.3	95.0	91.7
10-14	87.0	85.0	91.0	91.4	90.9	91.9	91.4	95.3	91.6	88.0	89.7	91.3	87.7	89.1	93.1	93.8	92.6
15-19	89.4	87.4	88.1	88.5	86.5	84.8	87.6	87.4	87.6	89.4	89.9	88.3	90.7	89.6	89.4	90.7	88.1
20-29	77.5	76.1	78.4	75.7	75.8	75.6	78.4	76.0	78.5	77.9	78.9	78.9	79.2	80.3	81.3	79.5	81.5
30-39	64.3	65.9	64.2	65.0	64.6	64.0	66.2	63.1	67.2	67.8	67.8	66.4	67.0	68.4	67.8	69.5	69.7
40-49	54.4	55.2	55.3	53.3	56.6	56.1	56.8	57.5	57.9	56.6	58.1	56.9	58.8	59.2	59.1	60.6	58.9
50-59	41.1	42.2	41.2	40.0	39.5	38.6	40.8	42.0	41.0	41.6	41.4	43.3	42.9	44.7	45.2	45.2	44.7
60-64	30.7	30.7	28.8	29.0	27.1	27.5	28.8	27.9	29.9	29.8	30.1	30.1	31.5	32.0	32.8	32.8	33.9
65-69	23.1	24.5	23.9	20.8	22.4	22.6	22.4	23.3	23.1	23.3	23.5	22.8	24.6	25.0	25.8	25.6	26.3
70-79	15.8	15.8	17.0	13.6	15.4	15.6	14.9	15.4	15.5	16.1	15.7	16.1	16.0	16.9	16.8	17.4	17.9
80+	7.0	5.8	5.9	6.4	7.5	8.3	7.5	7.7	6.7	8.9	8.6	7.7	7.5	8.0	8.2	8.7	8.6
Male	43.2	44.0	43.4	39.2	39.6	38.4	39.2	38.2	38.3	38.6	38.0	37.2	37.0	38.1	37.2	38.4	36.9
Female	43.6	45.1	43.1	38.7	39.6	38.8	38.4	37.4	37.7	36.5	36.0	35.1	35.6	35.3	35.4	34.9	34.3
White	43.3	43.4	42.0	37.4	37.7	37.1	36.8	35.4	34.8	34.5	33.7	32.7	32.7	33.0	32.5	32.2	31.3
Black	43.5	46.6	45.5	41.6	43.3	41.5	42.5	42.0	43.9	42.8	43.0	42.1	42.8	42.8	42.9	44.6	43.2
Other race	43.8	44.5	48.9	45.7	43.3	41.3	44.7	44.7	44.6	48.6	45.9	48.0	45.0	46.0	45.2	42.9	42.1
†Hispanic																	40.9
†Non-Hispanic																	35.1
Diabetes	28.8	27.5	26.7	26.7	26.4	26.4	28.2	27.2	28.1	28.1	27.3	27.7	28.4	29.6	29.2	28.8	28.7
Hypertension	44.0	40.6	39.0	35.3	35.8	35.3	34.0	32.5	33.4	33.4	33.5	31.8	32.7	33.3	32.3	34.2	33.5
Glomerulonephritis	64.9	61.9	61.4	58.2	57.7	55.4	56.2	55.6	57.1	56.4	56.1	55.3	56.7	58.2	56.2	57.4	56.7
Other cause	41.8	47.2	48.1	40.4	44.5	44.2	45.2	45.5	44.4	45.7	45.6	45.7	44.3	41.4	44.9	44.3	43.0
All	43.4	44.5	43.3	39.0	39.6	38.6	38.8	37.9	38.0	37.6	37.1	36.2	36.4	36.8	36.4	36.7	35.7
<b>ADJUSTED</b>																	
0-19	78.9	75.8	77.7	78.7	76.4	75.8	79.0	80.9	78.0	79.6	80.2	80.2	81.9	79.9	82.9	83.4	81.4
20-44	60.4	61.9	62.4	61.5	63.3	62.8	65.0	63.2	65.4	66.1	66.7	65.3	66.1	67.0	67.3	67.9	68.3
45-64	33.9	35.2	35.6	34.9	34.7	34.9	37.1	37.5	38.4	39.2	39.4	40.9	41.8	43.0	43.9	44.5	45.0
65-74	17.8	19.4	20.2	16.8	18.9	19.3	18.7	20.0	20.4	20.9	21.1	20.8	22.3	22.3	23.3	23.6	24.5
75+	10.1	9.9	10.3	8.3	10.1	10.7	10.7	10.3	9.8	11.7	10.7	11.2	10.4	11.1	11.3	12.0	12.4
Male	28.2	28.6	29.2	27.5	28.4	28.6	30.0	29.9	30.5	32.2	32.0	32.4	32.7	34.1	34.3	35.4	35.7
Female	29.8	31.5	31.8	30.0	31.5	31.8	32.4	32.6	33.0	33.2	33.6	33.9	34.8	34.8	35.8	35.7	36.5
White	27.0	27.4	28.1	26.3	27.5	28.1	28.7	28.7	29.1	30.4	30.2	30.6	31.4	32.0	32.9	33.1	34.0
Black	32.9	34.5	33.9	32.2	33.8	33.0	34.8	34.9	36.1	35.7	36.8	36.6	37.2	38.0	38.2	39.8	39.4
Other race	27.7	29.1	31.5	31.8	30.5	31.6	34.6	36.1	37.1	41.6	39.3	42.7	41.1	42.7	42.0	41.0	40.8
Diabetes	20.8	19.7	20.0	20.5	20.7	21.3	23.2	23.2	24.3	24.9	24.9	26.0	26.9	28.3	28.7	28.7	29.2
Hypertension	36.9	35.2	35.6	33.8	34.3	35.3	34.9	34.7	35.6	36.4	37.1	36.2	36.6	37.5	37.6	39.0	39.3
Glomerulonephritis	43.6	43.0	42.4	41.1	41.7	40.0	41.8	41.6	43.2	44.1	43.5	44.4	45.2	46.4	46.7	47.4	48.1
Other cause	33.0	35.3	36.5	33.1	36.1	36.0	37.4	38.0	37.1	38.8	38.4	38.7	38.8	38.3	39.5	39.1	39.0
All	28.9	29.9	30.4	28.7	29.9	30.1	31.1	31.2	31.7	32.7	32.7	33.1	33.7	34.4	35.1	35.6	36.1

**Standard Errors**

<b>UNADJUSTED</b>	<b>1980</b>	<b>1981</b>	<b>1982</b>	<b>1983</b>	<b>1984</b>	<b>1985</b>	<b>1986</b>	<b>1987</b>	<b>1988</b>	<b>1989</b>	<b>1990</b>	<b>1991</b>	<b>1992</b>	<b>1993</b>	<b>1994</b>	<b>1995</b>	<b>1996</b>
0-4	6.9	5.4	4.1	4.2	4.4	3.7	3.7	3.9	4.1	3.7	4.1	3.6	3.3	3.5	3.9	3.7	3.2
5-9	3.4	3.4	3.5	3.2	3.3	3.3	2.9	2.3	2.7	2.4	2.7	2.0	2.6	3.3	2.1	2.1	2.8
10-14	2.7	2.7	2.0	2.1	2.0	2.1	1.5	2.1	2.5	2.2	2.0	2.3	2.2	1.8	1.7	1.8	
15-19	1.6	1.6	1.6	1.6	1.7	1.8	1.6	1.6	1.6	1.4	1.5	1.6	1.4	1.5	1.5	1.4	1.6
20-29	1.1	1.1	1.0	1.0	1.0	1.0	0.9	1.0	0.9	0.9	0.9	0.9	0.8	0.8	0.8	0.9	0.9
30-39	1.1	1.0	0.9	0.9	0.9	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
40-49	1.1	1.0	1.0	0.9	0.9	0.9	0.8	0.8	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6
50-59	0.8	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5
60-64	1.1	1.0	0.9	0.8	0.8	0.8	0.8	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6
65-69	1.0	1.0	0.9	0.7	0.8	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5
70-79	0.8	0.8	0.7	0.5	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
80+	1.3	1.2	1.0	0.8	0.9	0.8	0.7	0.7	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4
Male	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Female	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3
White	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2
Black	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Other race	2.0	1.9	2.0	1.7	1.5	1.4	1.3	1.2	1.2	1.3	1.2	1.1	1.0	1.0	0.9	0.8	0.7
†Hispanic																	0.6
†Non-Hispanic																	0.2
Diabetes	1.0	0.8	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
Hypertension	1.0	0.8	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Glomerulonephritis	1.1	0.9	0.8	0.8	0.8	0.8	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6
Other cause	0.5	0.6	0.6	0.5	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4
All	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.  
The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, race, or primary diagnosis are excluded. Includes U.S. & territories; no unknown or foreign states.  
†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

**Table I.5**  
**Ten-year Survival Probabilities: Incident ESRD Patients**  
*from day 91 to ten years + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	73.0	70.0	76.4	75.3	69.8	72.6	80.4	78.8	65.2	75.8	72.9	76.0
5-9	80.5	79.5	77.3	81.6	85.3	81.9	84.0	82.1	91.4	86.9	85.3	89.8
10-14	77.3	76.9	76.6	83.9	82.3	83.3	84.9	88.4	82.7	78.4	80.5	85.9
15-19	79.6	79.7	79.3	80.0	78.4	75.5	78.2	78.5	78.6	82.7	83.5	79.1
20-29	63.8	62.3	65.4	63.2	63.0	64.0	64.8	64.1	66.8	64.6	67.0	65.0
30-39	46.7	47.2	47.5	48.6	48.5	46.6	49.2	47.3	49.1	49.6	50.9	49.3
40-49	31.9	32.4	33.4	33.0	35.3	35.4	35.9	35.4	35.7	34.3	35.3	34.9
50-59	15.5	17.6	17.5	16.3	16.8	17.2	18.0	19.2	17.5	17.9	18.2	19.0
60-64	7.7	8.0	6.2	8.3	8.1	9.0	8.7	8.2	8.8	8.3	8.2	8.4
65-69	4.6	5.0	3.9	4.8	5.3	6.2	5.1	4.7	4.9	4.7	5.3	4.8
70-79	2.4	2.0	2.8	2.1	2.8	2.7	2.3	2.5	2.2	2.1	2.0	1.8
80+	1.4	0.5	1.3	0.2	1.2	0.8	0.6	0.8	0.4	0.6	0.3	0.6
Male	24.1	25.0	25.3	22.8	23.1	22.5	22.8	21.6	21.0	20.6	20.8	19.4
Female	24.2	25.2	23.7	21.1	21.9	21.2	20.4	19.5	19.4	18.2	17.5	17.1
White	25.5	25.8	25.1	22.5	22.7	22.1	21.7	20.5	19.3	18.7	18.5	17.4
Black	21.5	23.3	22.7	20.3	21.5	21.0	20.7	19.9	21.4	20.4	19.9	19.2
Other race	26.3	28.1	31.0	28.8	27.4	25.8	28.2	26.3	26.3	27.3	26.9	26.5
Diabetes	11.5	11.4	11.5	11.0	11.5	11.8	12.0	11.6	11.1	10.9	10.2	9.6
Hypertension	21.1	19.3	17.9	16.5	17.0	16.0	15.9	14.1	14.6	14.4	14.4	13.7
Glomerulonephritis	45.8	41.5	42.0	40.0	39.8	39.1	39.7	38.2	39.0	37.9	38.4	36.4
Other cause	23.1	27.6	29.1	24.5	27.4	27.6	27.7	26.9	27.5	28.4	28.9	
All	24.2	25.1	24.6	22.0	22.6	21.9	21.7	20.6	20.3	19.5	19.3	18.3
<b>ADJUSTED</b>												
0-19	65.3	64.7	63.3	67.2	65.8	63.4	68.2	69.1	66.0	69.6	70.0	69.7
20-44	42.0	42.5	44.4	44.4	45.8	45.8	47.2	45.9	47.2	47.5	48.6	47.2
45-64	11.5	13.0	13.5	13.6	14.3	15.0	16.0	16.3	16.1	16.5	16.7	17.5
65-74	2.9	3.2	3.2	3.3	3.9	4.6	3.8	3.7	3.7	3.8	4.1	3.7
75+	1.2	1.1	1.5	0.7	1.6	1.4	1.1	1.4	1.2	1.0	0.8	1.0
Male	12.5	12.9	13.7	13.4	14.1	14.6	15.1	14.9	14.7	15.2	15.5	15.3
Female	13.7	14.7	14.7	14.4	15.5	15.7	15.4	15.7	15.7	15.5	15.6	15.9
White	12.8	13.1	13.7	13.5	14.4	14.7	14.8	14.9	14.5	15.0	15.2	15.3
Black	13.2	13.9	13.7	13.2	14.1	14.5	14.5	14.4	15.1	14.5	14.9	14.8
Other race	13.2	14.6	16.3	16.1	16.4	17.1	18.4	18.6	19.3	20.3	20.2	20.7
Diabetes	7.6	7.7	8.1	8.1	8.6	9.3	9.4	9.6	9.4	9.4	9.4	9.3
Hypertension	16.1	15.8	16.0	16.0	16.3	16.5	16.5	16.2	16.3	16.4	16.8	16.5
Glomerulonephritis	22.8	22.0	22.1	22.3	23.4	23.3	24.3	23.5	24.0	24.0	24.1	24.2
Other cause	15.9	17.3	18.3	17.3	19.2	19.6	19.5	20.0	19.6	20.2	20.7	21.4
All	13.0	13.7	14.2	13.8	14.7	15.1	15.2	15.1	15.3	15.6	15.6	

**Standard Errors**

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	7.2	5.9	4.5	4.4	4.7	4.2	3.8	4.0	4.5	3.9	4.5	3.8
5-9	4.3	4.4	4.2	4.1	3.6	3.9	3.5	3.9	3.1	3.4	3.3	2.9
10-14	3.4	3.2	3.0	2.7	2.6	2.7	2.6	2.3	2.8	3.2	2.9	2.4
15-19	2.0	1.9	2.0	2.0	2.1	2.2	2.1	2.0	1.8	1.8	1.8	2.0
20-29	1.3	1.2	1.1	1.2	1.1	1.1	1.1	1.1	1.0	1.0	1.0	1.0
30-39	1.1	1.0	1.0	1.0	0.9	0.9	0.9	0.9	0.8	0.8	0.8	0.8
40-49	1.0	0.9	0.9	0.9	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.6
50-59	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4
60-64	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4
65-69	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
70-79	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.1	0.1
80+	0.6	0.3	0.5	0.1	0.4	0.3	0.2	0.2	0.1	0.2	0.1	0.1
Male	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2
Female	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
White	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2
Black	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3
Other race	1.7	1.7	1.9	1.5	1.4	1.3	1.2	1.1	1.1	1.1	1.0	1.0
Diabetes	0.7	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.2	0.2
Hypertension	0.8	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3
Glomerulonephritis	1.1	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.7	0.7	0.6	0.6
Other cause	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4
All	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.  
The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, race, or primary diagnosis are excluded. Includes U.S. & territories; no unknown or foreign states.

**Table I.6**  
**Incident Patient Counts: ESRD Patients Aged 65 & Over**

patients aged 65 & over on day 1

	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99	2000-01
65-69	4,302	5,850	7,332	9,420	11,915	15,005	17,245	18,867	20,598	21,572	21,897
70-74	3,221	4,974	6,327	8,062	10,131	13,336	16,473	18,883	21,545	23,170	23,816
75-79	1,860	3,013	4,239	5,762	7,670	9,909	12,192	14,365	17,520	20,884	22,180
80-84	678	1,214	1,821	2,637	3,728	5,119	6,603	8,160	10,529	12,699	14,406
85+	203	435	646	932	1,413	2,068	2,736	3,413	4,753	6,580	7,772
Male	5,636	8,309	10,766	13,999	18,108	23,427	28,177	32,049	38,593	43,827	46,625
Female	4,628	7,177	9,599	12,814	16,749	22,010	27,072	31,639	36,352	41,078	43,446
White	6,906	11,187	14,645	19,261	25,228	32,830	39,463	45,484	53,602	61,603	66,069
Black	2,977	3,891	5,011	6,490	8,438	11,072	13,623	15,001	17,226	18,819	19,471
Other race	381	408	709	1,062	1,191	1,535	2,163	3,203	4,117	4,483	4,531
†Hispanic									6,641	7,678	8,351
†Non-Hispanic									68,304	77,227	81,720
Diabetes	1,225	2,615	4,215	6,447	9,515	14,086	17,758	23,251	30,529	35,464	38,723
Hypertension	2,583	5,208	7,270	10,074	13,812	18,216	21,185	23,267	25,529	28,964	30,564
Glomerulonephritis	1,027	1,825	2,387	2,868	3,445	4,131	4,265	5,058	5,610	5,618	5,062
Cystic kidney	269	420	466	571	600	735	758	951	994	1,041	1,047
Other urologic	341	439	634	778	920	1,117	1,149	1,261	1,563	1,643	1,632
Other cause	981	1,958	2,605	3,148	3,515	3,650	3,965	5,229	6,846	7,781	8,539
Unknown cause	1,186	1,245	1,369	1,871	2,049	2,317	2,590	2,707	3,342	3,845	4,178
Missing cause	2,652	1,776	1,419	1,056	1,001	1,185	3,579	1,964	532	549	326
All	10,264	15,486	20,365	26,813	34,857	45,437	55,249	63,688	74,945	84,905	90,071

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes patients from U.S. & territories only.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

**Table I.7**  
**One-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over**  
*from day 1 to one year, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99	2000-01
65-69	70.9	70.8	69.8	72.0	73.0	73.8	75.2	75.7	75.5	74.9	74.9
70-74	66.3	67.1	64.9	66.2	66.7	68.2	70.1	70.3	69.8	69.6	69.2
75-79	60.9	60.3	61.8	60.8	61.2	63.7	63.5	64.5	64.2	63.2	63.6
80-84	53.5	56.8	55.5	56.5	57.4	57.6	59.1	58.9	58.6	56.5	56.2
85+	46.3	50.8	47.2	48.9	47.0	51.1	51.0	51.8	48.8	47.4	48.3
Male	64.9	63.8	62.8	63.7	64.2	65.8	67.1	67.2	66.5	65.4	65.2
Female	67.3	68.4	66.7	67.5	67.6	68.5	68.9	69.1	67.9	66.0	65.6
White	64.7	63.7	62.3	62.6	63.1	64.3	65.1	65.6	65.0	63.8	63.6
Black	68.7	72.3	71.0	73.6	73.3	74.2	74.8	74.5	72.6	70.4	69.7
Other race	68.0	65.9	66.7	69.0	71.7	76.4	77.1	74.9	73.0	71.7	73.1
†Hispanic									71.1	70.8	70.8
†Non-Hispanic									66.8	65.2	64.8
Diabetes	64.2	61.2	63.4	65.1	66.7	68.2	70.0	69.8	69.2	67.8	67.7
Hypertension	68.3	65.8	65.0	64.8	64.4	65.6	65.7	66.8	66.3	64.9	64.4
Glomerulonephritis	74.1	73.6	73.4	72.5	72.5	72.8	74.9	73.9	74.4	73.5	74.0
Other cause	63.8	65.7	61.7	64.3	64.5	66.0	66.7	65.2	61.0	59.2	58.7
All	66.0	65.9	64.6	65.5	65.9	67.1	68.0	68.2	67.1	65.7	65.4
<b>ADJUSTED</b>											
65-69	68.6	69.2	68.6	71.1	72.5	73.6	75.0	75.7	75.7	75.3	75.4
70-74	64.4	65.9	63.7	65.4	66.1	67.9	69.9	70.3	70.0	69.9	69.7
75-79	59.5	59.0	60.8	59.9	60.5	63.3	63.1	64.3	64.2	63.4	64.0
80-84	52.4	55.9	54.6	55.8	56.8	57.0	58.6	58.6	58.5	56.5	56.4
85+	45.7	49.9	46.1	48.0	46.0	50.3	50.3	51.2	48.2	47.1	48.2
Male	60.4	60.4	59.9	61.3	62.3	64.4	66.0	66.6	66.5	66.2	66.4
Female	62.4	64.7	63.5	64.9	65.6	67.0	67.7	68.3	67.7	66.5	66.6
White	60.1	59.8	59.1	59.9	61.0	62.8	64.1	65.0	65.0	64.6	64.8
Black	65.2	69.6	68.5	71.4	71.3	72.5	73.5	73.4	71.9	69.9	69.6
Other race	63.6	63.3	64.0	66.9	70.2	74.9	76.0	74.0	72.8	72.1	73.8
Diabetes	57.8	56.0	58.6	60.4	62.7	64.6	66.7	67.0	66.9	66.0	66.4
Hypertension	65.6	64.0	63.7	64.0	64.2	65.8	66.2	67.6	67.8	67.1	67.2
Glomerulonephritis	71.4	71.7	72.0	71.3	71.8	72.5	74.8	74.2	75.0	74.6	75.1
Other cause	61.3	64.1	60.7	63.5	64.0	65.6	66.6	65.5	62.2	61.1	60.8
All	61.4	62.4	61.6	63.0	63.9	65.7	66.8	67.4	67.1	66.4	66.5

**Standard Errors**

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99	2000-01
65-69	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.3
70-74	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3
75-79	1.1	0.9	0.7	0.6	0.6	0.5	0.4	0.4	0.4	0.3	0.4
80-84	1.9	1.4	1.2	1.0	0.8	0.7	0.6	0.5	0.5	0.4	0.5
85+	3.5	2.4	2.0	1.6	1.3	1.1	1.0	0.9	0.7	0.6	0.7
Male	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.3
Female	0.7	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.3
White	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2
Black	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.4
Other race	2.4	2.3	1.8	1.4	1.3	1.1	0.9	0.8	0.7	0.7	0.8
†Hispanic										0.6	0.5
†Non-Hispanic										0.2	0.2
Diabetes	1.4	1.0	0.7	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.3
Hypertension	0.9	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.3
Glomerulonephritis	1.4	1.0	0.9	0.8	0.8	0.7	0.7	0.6	0.6	0.6	0.7
Other cause	0.7	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.5
All	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
<b>ADJUSTED</b>											
65-69	0.8	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.3
70-74	0.9	0.7	0.6	0.5	0.5	0.4	0.3	0.3	0.3	0.3	0.3
75-79	1.2	0.9	0.8	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.4
80-84	2.1	1.4	1.2	1.0	0.8	0.7	0.6	0.6	0.5	0.5	0.5
85+	3.5	2.4	2.0	1.6	1.4	1.1	1.0	0.9	0.7	0.6	0.7
Male	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.3
Female	0.8	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.3
White	0.6	0.5	0.5	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2
Black	0.9	0.8	0.7	0.6	0.5	0.4	0.4	0.4	0.4	0.3	0.4
Other race	2.4	2.3	1.9	1.5	1.3	1.2	0.9	0.8	0.7	0.7	0.8
Diabetes	1.6	1.0	0.8	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3
Hypertension	0.9	0.7	0.6	0.5	0.4	0.3	0.3	0.3	0.3	0.3	0.3
Glomerulonephritis	1.5	1.1	1.0	0.9	0.8	0.7	0.6	0.6	0.6	0.6	0.7
Other cause	0.7	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4
All	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.  
The age of the incident patient is determined as of the date of ESRD initiation.  
Patients of unknown age, gender, race, or primary diagnosis are excluded.  
Includes U.S. & territories; no unknown or foreign states.  
†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



**Table I.8**  
**Two-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over**  
*from day 1 to two years, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99
65-69	53.1	52.1	51.8	53.5	55.3	56.0	58.2	58.7	59.0	58.4
70-74	47.2	47.8	46.5	47.1	48.0	49.2	51.0	51.9	51.5	52.0
75-79	41.5	39.2	41.1	40.5	41.7	43.6	44.4	45.1	44.8	44.5
80-84	33.5	34.4	35.8	33.8	35.6	36.6	38.1	38.7	38.1	36.7
85+	27.1	29.0	27.1	26.8	28.4	28.4	29.2	30.0	28.8	28.0
Male	45.8	43.5	43.2	43.8	45.2	46.5	47.9	48.4	47.9	47.5
Female	49.2	49.3	48.6	48.3	48.9	49.3	50.5	50.6	49.5	47.8
White	46.0	43.7	43.2	42.7	43.8	44.4	45.5	46.3	45.8	45.2
Black	50.7	53.5	52.8	55.2	55.6	56.4	57.9	57.5	55.9	53.7
Other race	45.1	45.6	46.7	48.5	53.2	59.8	60.9	57.2	55.7	55.2
†Hispanic									52.7	53.0
†Non-Hispanic									48.3	47.1
Diabetes	40.7	38.9	41.9	42.4	44.9	46.6	49.5	49.5	49.2	48.6
Hypertension	49.3	46.1	46.7	45.1	46.2	46.6	47.2	48.7	48.3	46.9
Glomerulonephritis	55.8	55.8	54.3	53.7	54.5	55.5	57.7	56.7	57.1	57.1
Other cause	46.3	46.5	44.0	47.2	47.6	48.9	49.1	48.1	44.6	43.2
All	47.3	46.2	45.7	45.9	47.0	47.9	49.2	49.5	48.7	47.6
<b>ADJUSTED</b>										
65-69	49.7	49.7	49.9	52.1	54.5	55.6	57.8	58.8	59.4	59.0
70-74	44.6	45.9	44.9	45.9	47.1	48.7	50.6	51.8	51.8	52.5
75-79	39.5	37.4	39.7	39.2	40.7	42.9	43.9	44.8	44.9	44.9
80-84	32.0	33.2	34.6	32.8	34.8	35.7	37.3	38.3	37.9	36.8
85+	26.4	27.8	25.8	25.8	27.3	27.5	28.3	29.3	28.2	27.7
Male	40.2	39.2	39.6	40.7	42.8	44.7	46.4	47.7	47.9	48.4
Female	42.9	44.5	44.7	44.8	46.3	47.2	48.8	49.6	49.3	48.5
White	40.1	38.8	39.2	39.3	41.2	42.5	44.1	45.6	45.9	46.2
Black	46.1	49.6	49.4	52.1	52.8	54.1	55.9	55.9	54.9	53.1
Other race	39.5	42.0	43.4	45.6	51.3	57.8	59.4	56.0	55.5	55.8
Diabetes	33.7	33.3	36.5	36.9	40.1	42.2	45.3	45.9	46.2	46.4
Hypertension	46.0	44.0	45.1	44.1	45.9	46.8	47.9	49.8	50.2	49.6
Glomerulonephritis	52.2	53.3	52.4	52.2	53.7	55.3	57.5	57.3	58.1	58.7
Other cause	43.4	44.5	42.9	46.3	47.0	48.4	48.9	48.5	46.1	45.4
All	41.5	41.7	42.0	42.7	44.5	45.9	47.6	48.6	48.6	48.5

**Standard Errors**

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99
65-69	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3
70-74	0.9	0.7	0.6	0.6	0.5	0.4	0.4	0.4	0.4	0.3
75-79	1.1	0.9	0.8	0.6	0.6	0.5	0.4	0.4	0.4	0.3
80-84	1.8	1.4	1.1	0.9	0.8	0.7	0.6	0.5	0.5	0.4
85+	3.1	2.2	1.7	1.4	1.2	1.0	0.9	0.8	0.7	0.6
Male	0.7	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.2
Female	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.2
White	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.2
Black	0.9	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.4	0.4
Other race	2.5	2.5	1.9	1.5	1.4	1.3	1.0	0.9	0.8	0.7
†Hispanic									0.6	0.6
†Non-Hispanic									0.2	0.2
Diabetes	1.4	1.0	0.8	0.6	0.5	0.4	0.4	0.3	0.3	0.3
Hypertension	1.0	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3
Glomerulonephritis	1.5	1.2	1.0	0.9	0.8	0.8	0.8	0.7	0.7	0.7
Other cause	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4
All	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2
<b>ADJUSTED</b>										
65-69	0.8	0.7	0.6	0.5	0.4	0.4	0.4	0.3	0.3	0.3
70-74	0.9	0.7	0.6	0.6	0.5	0.4	0.4	0.3	0.3	0.3
75-79	1.1	0.9	0.8	0.6	0.6	0.5	0.5	0.4	0.4	0.3
80-84	1.8	1.3	1.2	0.9	0.8	0.7	0.6	0.5	0.5	0.4
85+	2.9	2.2	1.7	1.4	1.2	1.0	0.9	0.8	0.7	0.6
Male	0.7	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.2
Female	0.7	0.6	0.5	0.5	0.4	0.3	0.3	0.3	0.3	0.2
White	0.6	0.5	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.2
Black	1.0	0.8	0.7	0.7	0.6	0.5	0.4	0.4	0.4	0.4
Other race	2.5	2.4	1.9	1.6	1.4	1.3	1.1	0.9	0.8	0.7
Diabetes	1.4	0.9	0.7	0.6	0.5	0.4	0.4	0.4	0.3	0.3
Hypertension	1.0	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3
Glomerulonephritis	1.7	1.2	1.0	0.9	0.8	0.8	0.7	0.7	0.6	0.7
Other cause	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4
All	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule  
The age of the incident patient is determined as of the date of ESRD initiation.  
Patients of unknown age, gender, race, or primary diagnosis are excluded.  
Includes U.S. & territories; no unknown or foreign states.  
†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

**Table I.9**  
**Five-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over**  
*from day 1 to five years, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97
65-69	23.1	21.5	22.0	22.4	23.1	23.0	24.6	25.5	25.9
70-74	16.7	16.5	16.8	16.4	17.5	17.6	18.8	19.3	19.3
75-79	12.8	11.1	11.9	12.6	12.5	12.7	12.7	13.5	14.3
80-84	6.2	6.9	8.7	7.9	8.5	8.9	8.7	9.0	9.3
85+	4.4	3.7	3.7	4.7	5.3	5.2	5.3	5.6	5.1
Male	16.2	14.1	14.6	14.9	16.0	16.0	16.2	16.9	17.1
Female	19.6	18.6	18.7	18.2	17.8	17.7	18.6	18.7	18.1
White	16.6	14.9	14.8	14.3	14.7	14.2	14.8	15.2	15.4
Black	20.5	20.1	21.5	22.5	22.7	23.4	23.7	24.5	23.1
Other race	16.3	14.5	16.4	18.3	21.7	24.2	24.2	23.1	23.4
†Hispanic									19.9
†Non-Hispanic									17.4
Diabetes	11.3	10.2	12.1	12.3	12.9	13.7	15.1	15.8	15.8
Hypertension	19.0	16.8	16.4	16.0	16.4	16.3	16.5	17.4	17.8
Glomerulonephritis	23.1	22.9	21.1	21.5	22.8	23.0	24.3	24.4	25.1
Other cause	17.6	16.2	17.9	18.7	19.7	19.9	19.8	19.7	18.4
All	17.7	16.2	16.5	16.5	16.8	16.8	17.4	17.8	17.6
<b>ADJUSTED</b>									
65-69	19.7	19.1	20.1	20.8	22.1	22.4	24.1	25.5	26.4
70-74	14.7	14.8	15.5	15.4	16.6	17.0	18.3	19.1	19.5
75-79	11.0	10.0	10.8	11.5	11.8	12.2	12.2	13.3	14.3
80-84	5.7	6.3	8.0	7.4	8.1	8.4	8.3	8.8	9.2
85+	4.2	3.2	3.3	4.4	4.8	4.9	5.0	5.3	5.0
Male	12.1	11.2	12.1	12.8	14.1	14.6	15.0	16.2	17.1
Female	14.5	14.7	15.5	15.4	15.7	15.9	17.2	17.7	18.0
White	12.1	11.3	11.9	11.9	12.7	12.8	13.7	14.6	15.4
Black	16.5	16.6	18.6	19.7	20.1	21.3	21.6	22.8	22.2
Other race	12.5	12.0	14.1	16.0	20.1	22.3	22.5	22.0	23.2
Diabetes	7.8	7.5	9.3	9.3	10.1	11.0	12.4	13.3	13.7
Hypertension	16.2	15.2	15.1	15.3	16.1	16.5	16.9	18.2	19.3
Glomerulonephritis	20.1	21.0	19.8	20.4	22.4	22.9	24.3	24.8	26.1
Other cause	15.5	14.9	17.1	18.1	19.3	19.4	19.6	20.0	19.6
All	13.2	12.8	13.7	14.0	14.9	15.2	16.0	17.0	17.6

**Standard Errors**

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97
65-69	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3
70-74	0.7	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3
75-79	0.8	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3
80-84	0.9	0.7	0.7	0.5	0.5	0.4	0.3	0.3	0.3
85+	1.4	0.9	0.7	0.7	0.6	0.5	0.4	0.4	0.4
Male	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2
Female	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2
White	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2
Black	0.7	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.3
Other race	1.9	1.7	1.4	1.2	1.2	1.1	0.9	0.7	0.7
†Hispanic									0.5
†Non-Hispanic									0.2
Diabetes	0.9	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.2
Hypertension	0.8	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.3
Glomerulonephritis	1.3	1.0	0.8	0.8	0.7	0.7	0.7	0.6	0.6
Other cause	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4
All	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.1
<b>ADJUSTED</b>									
65-69	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3
70-74	0.6	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3
75-79	0.7	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3
80-84	0.8	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.3
85+	1.3	0.8	0.7	0.7	0.5	0.5	0.4	0.4	0.4
Male	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2
Female	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2
White	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
Black	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3
Other race	1.6	1.5	1.3	1.1	1.1	1.0	0.8	0.7	0.7
Diabetes	0.7	0.5	0.4	0.3	0.3	0.2	0.2	0.2	0.2
Hypertension	0.7	0.5	0.4	0.3	0.3	0.3	0.3	0.3	0.3
Glomerulonephritis	1.2	0.9	0.8	0.7	0.7	0.6	0.6	0.6	0.6
Other cause	0.5	0.4	0.5	0.5	0.4	0.4	0.4	0.3	0.3
All									

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.  
The age of the incident patient is determined as of the date of ESRD initiation.  
Patients of unknown age, gender, race, or primary diagnosis are excluded.  
Includes U.S. & territories; no unknown or foreign states.  
†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

**Table I.10**  
**Ten-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over**  
*from day 1 to ten years, by age, gender, & race, ethnicity, & primary diagnosis*

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93
65-69	4.8	4.3	5.8	4.9	4.8	5.0	5.0
70-74	2.6	2.8	3.1	2.8	2.6	2.4	2.9
75-79	1.5	1.4	1.7	1.8	1.4	1.2	1.1
80-84	0.9	0.8	1.0	0.8	0.6	0.5	0.4
85+	0.5	.	0.5	0.1	0.4	0.3	0.4
Male	2.8	2.3	3.2	3.0	2.5	2.5	2.6
Female	3.7	3.6	3.8	3.1	3.1	2.9	2.8
White	2.9	2.5	3.2	2.7	2.2	2.1	2.3
Black	4.0	3.9	4.4	3.8	4.1	3.9	4.0
Other race	1.6	3.4	3.4	4.6	4.2	4.8	2.5
Diabetes	1.7	1.8	2.3	1.7	1.5	1.5	1.5
Hypertension	2.7	2.5	3.0	2.6	2.3	2.3	2.4
Glomerulonephritis	3.6	4.2	4.8	5.0	4.7	4.5	4.9
Other cause	3.6	3.3	4.4	4.1	4.2	4.3	4.5
All	3.2	2.9	3.5	3.1	2.8	2.7	2.7
<b>ADJUSTED</b>							
65-69	3.6	3.5	4.9	4.3	4.3	4.7	4.8
70-74	2.0	2.3	2.7	2.6	2.3	2.2	2.7
75-79	1.1	1.1	1.5	1.5	1.2	1.1	1.1
80-84	0.8	0.8	0.9	0.7	0.5	0.5	0.4
85+	0.5	.	0.4	0.1	0.3	0.3	0.4
Male	1.7	1.5	2.4	2.3	1.9	2.1	2.3
Female	2.2	2.3	2.8	2.3	2.4	2.4	2.4
White	1.6	1.5	2.2	1.9	1.7	1.7	1.9
Black	2.7	2.7	3.3	3.0	3.2	3.3	3.3
Other race	1.1	2.7	2.7	3.6	3.6	3.9	2.6
Diabetes	1.1	1.2	1.7	1.2	1.1	1.1	1.1
Hypertension	2.1	2.1	2.7	2.5	2.3	2.4	2.5
Glomerulonephritis	2.8	3.9	4.5	4.7	4.5	4.6	5.0
Other cause	3.0	2.9	4.1	3.9	4.1	4.1	4.5
All	1.9	1.9	2.6	2.3	2.2	2.2	2.4

**Standard Errors**

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93
65-69	0.3	0.3	0.3	0.2	0.2	0.2	0.4
70-74	0.3	0.2	0.2	0.2	0.2	0.1	0.2
75-79	0.3	0.2	0.2	0.2	0.1	0.1	0.2
80-84	0.3	0.3	0.2	0.2	0.1	0.1	0.2
85+	0.4	.	0.2	0.1	0.2	0.1	0.2
Male	0.2	0.2	0.2	0.1	0.1	0.1	0.2
Female	0.3	0.2	0.2	0.2	0.1	0.1	0.2
White	0.2	0.1	0.1	0.1	0.1	0.1	0.1
Black	0.4	0.3	0.3	0.2	0.2	0.2	0.3
Other race	0.6	0.9	0.7	0.6	0.6	0.5	1.3
Diabetes	0.4	0.3	0.2	0.2	0.1	0.1	0.3
Hypertension	0.3	0.2	0.2	0.2	0.1	0.1	0.2
Glomerulonephritis	0.6	0.5	0.4	0.4	0.4	0.3	0.5
Other cause	0.3	0.2	0.3	0.2	0.2	0.2	0.3
All	0.2	0.1	0.1	0.1	0.1	0.1	0.1

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

"." Zero values in this cell.

**Table I.11  
Incident Patient Counts: Dialysis Patients**

*dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	23	44	61	73	78	88	87	75	84	95	72	105	92	83	79	95	102	91	83	76	104
5-9	53	52	68	67	69	54	74	67	56	61	80	61	51	60	86	67	66	55	59	72	63
10-14	118	139	161	141	149	130	119	119	122	103	129	139	147	142	151	154	162	147	138	133	147
15-19	328	360	339	349	316	314	305	324	337	387	337	321	374	333	319	360	360	292	331	335	306
20-29	1,193	1,373	1,557	1,499	1,615	1,651	1,696	1,699	1,770	1,886	1,941	1,990	2,079	2,016	2,000	1,946	1,950	1,802	1,850	1,726	1,794
30-39	1,843	2,109	2,364	2,426	2,593	2,752	2,967	2,980	3,298	3,661	3,765	3,966	4,242	4,147	4,300	4,302	4,179	3,974	3,945	4,085	3,906
40-49	2,118	2,456	2,551	2,863	2,955	3,228	3,421	3,783	4,100	4,732	5,037	5,696	6,142	6,308	6,650	7,123	7,282	7,055	7,605	7,589	7,757
50-59	3,357	3,999	4,264	4,388	4,623	4,919	5,115	5,446	6,107	6,609	7,050	7,619	8,436	8,580	9,695	9,901	9,984	10,697	11,446	12,181	12,451
60-64	1,899	2,170	2,454	2,873	3,165	3,467	3,600	4,038	4,404	4,778	5,112	5,694	5,983	6,079	6,469	6,789	6,860	7,007	7,397	7,547	7,757
65-69	1,932	1,961	2,260	3,040	3,074	3,501	4,013	4,566	5,076	5,874	6,511	7,269	7,805	8,107	8,771	8,638	9,341	9,605	9,854	9,953	9,942
70-79	2,142	2,302	2,882	4,144	4,261	4,954	5,708	6,515	7,179	8,526	9,510	11,232	12,501	13,079	14,729	14,965	16,781	17,849	18,910	20,074	20,412
80+	357	376	539	846	909	1,131	1,377	1,613	1,951	2,403	2,792	3,263	3,815	4,121	4,674	5,036	5,986	6,774	7,470	8,382	9,039
Male	8,510	9,512	10,658	12,391	13,084	14,179	15,471	16,800	18,487	21,124	22,805	25,311	27,342	28,282	30,694	31,464	33,809	34,893	36,918	38,834	39,694
Female	6,853	7,829	8,842	10,318	10,723	12,010	13,011	14,425	15,997	17,991	19,531	22,044	24,325	24,773	27,229	27,912	29,244	30,455	32,170	33,319	33,984
White	9,349	10,903	13,036	14,769	15,542	17,090	18,541	20,095	22,083	25,106	27,277	30,411	33,006	33,220	36,613	36,802	38,983	41,666	43,661	46,452	47,820
Black	5,419	5,778	5,880	7,113	7,248	7,969	8,592	9,607	10,732	12,534	13,321	14,963	16,363	17,327	18,305	18,626	19,641	19,797	21,031	21,327	21,324
Other race	595	660	584	827	1,017	1,130	1,349	1,523	1,669	1,475	1,738	1,981	2,298	2,508	3,005	3,948	4,429	3,885	4,396	4,374	4,534
†Hispanic																	7,203	7,071	7,797	8,140	8,624
†Non-Hispanic																	55,850	58,277	61,291	64,013	65,054
Diabetes	2,055	3,276	4,544	5,327	6,462	7,488	8,595	9,624	10,915	13,300	14,972	17,473	19,458	19,244	22,424	24,729	27,815	29,482	31,480	32,989	34,261
Hypertension	2,369	3,726	4,993	5,458	6,119	7,019	7,629	8,660	9,787	11,606	12,513	14,176	15,801	15,103	17,238	15,492	16,760	17,689	18,682	19,634	19,913
Glomerulonephritis	1,939	2,803	3,509	3,706	3,924	4,091	4,192	4,409	4,734	5,049	5,309	5,637	5,847	5,695	6,151	6,264	6,646	6,394	6,436	6,358	6,140
Cystic kidney	588	797	964	996	1,014	1,066	1,118	1,154	1,134	1,151	1,251	1,321	1,400	1,355	1,474	1,508	1,433	1,479	1,535	1,597	1,546
Other urologic	246	355	371	443	446	567	563	589	635	695	729	975	1,023	880	940	1,055	1,288	1,175	1,203	1,303	1,242
Other cause	1,400	2,020	2,785	3,132	3,329	3,638	3,711	3,816	3,879	4,290	4,159	4,356	4,626	4,516	4,948	6,028	6,270	6,415	6,829	7,082	7,370
Unknown cause	1,236	1,419	1,211	1,208	1,260	1,243	1,473	1,719	1,701	1,557	1,639	1,982	2,169	1,926	1,986	2,014	2,288	2,366	2,615	2,622	2,819
Missing cause	5,530	2,945	1,123	2,439	1,253	1,077	1,201	1,254	1,699	1,467	1,764	1,435	1,343	4,336	2,762	2,286	553	348	308	568	387
All	15,363	17,341	19,500	22,709	23,807	26,189	28,482	31,225	34,484	39,115	42,336	47,355	51,667	53,055	57,923	59,376	63,053	65,348	69,088	72,153	73,678

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

**Table I.12**

**One-year Survival Probabilities: Incident Dialysis Patients**

*censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

<b>UNADJUSTED</b>	<b>1980</b>	<b>1981</b>	<b>1982</b>	<b>1983</b>	<b>1984</b>	<b>1985</b>	<b>1986</b>	<b>1987</b>	<b>1988</b>	<b>1989</b>	<b>1990</b>	<b>1991</b>	<b>1992</b>	<b>1993</b>	<b>1994</b>	<b>1995</b>	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>
0-4	94.4	91.3	89.5	89.2	83.8	85.9	93.8	96.9	80.1	85.3	85.5	80.3	87.2	85.7	90.2	85.7	91.5	85.1	86.1	90.2	84.9
5-9	91.2	95.6	95.4	98.1	88.8	88.5	100.0	100.0	100.0	100.0	94.5	95.1	94.1	96.2	100.0	98.4	93.7	95.8	100.0	96.9	98.1
10-14	96.8	98.4	97.4	98.1	96.6	98.0	98.7	98.8	96.4	94.9	96.2	97.3	94.0	92.8	99.1	98.2	97.5	94.4	98.1	95.9	95.6
15-19	96.2	94.4	94.7	94.5	96.4	93.5	94.2	94.8	96.6	97.9	96.9	95.3	97.0	96.3	95.5	97.4	96.9	97.9	94.6	97.9	96.3
20-29	90.1	92.3	92.3	92.4	92.1	90.5	92.9	90.5	91.7	91.5	91.9	91.7	92.9	92.0	93.1	92.2	94.3	95.7	95.3	95.2	93.2
30-39	88.3	89.0	88.1	89.2	87.1	87.5	88.0	87.2	88.6	88.1	89.2	88.3	89.3	88.8	89.2	89.3	90.0	91.5	90.9	91.3	91.3
40-49	87.4	87.3	86.0	87.2	86.9	86.4	86.5	86.9	87.6	87.6	88.7	87.0	87.7	88.7	88.8	89.3	89.6	89.9	88.8	89.5	89.9
50-59	83.0	83.4	83.9	81.3	81.7	81.6	81.9	82.6	83.0	82.5	83.7	83.7	84.7	84.7	85.5	85.9	85.4	85.6	85.4	85.8	85.4
60-64	77.9	77.0	77.3	76.9	75.4	75.7	76.4	75.8	76.0	77.3	78.0	78.5	79.3	80.7	81.0	80.0	81.6	81.8	80.1	81.2	80.9
65-69	72.8	73.5	73.4	71.9	72.7	71.0	73.0	73.1	73.2	73.8	75.4	75.0	75.4	77.1	76.2	77.0	77.5	76.5	75.8	76.1	76.5
70-79	66.8	67.9	68.2	65.3	66.2	66.6	66.3	65.4	65.8	67.3	68.3	68.2	68.3	69.9	70.0	70.2	70.5	69.5	69.5	69.2	69.1
80+	58.0	53.7	62.0	55.1	56.8	57.8	58.7	55.4	55.4	57.8	59.3	59.2	58.2	60.9	60.7	60.2	60.0	59.3	57.3	58.1	58.0
Male	79.7	80.5	79.9	77.2	77.2	76.5	76.4	76.2	76.0	76.8	77.8	77.2	77.4	78.7	78.4	78.4	78.5	78.0	77.2	77.6	77.2
Female	80.5	80.8	80.6	78.2	78.3	77.6	78.3	76.8	77.8	77.5	78.2	77.4	77.9	78.3	78.4	78.6	78.3	77.4	76.6	76.3	76.3
White	78.7	79.1	78.3	75.4	74.8	74.5	74.4	73.3	73.7	74.1	74.9	74.1	74.4	75.4	75.5	75.6	75.5	74.4	73.9	74.2	74.0
Black	82.2	83.5	83.9	81.9	83.2	81.8	82.4	82.5	82.4	82.2	83.3	82.6	83.2	83.3	83.1	83.1	83.2	83.4	81.9	82.0	81.5
Other race	80.6	80.2	83.6	80.5	80.7	80.1	82.1	78.6	81.1	83.9	84.5	85.8	84.1	86.2	84.6	84.3	82.1	83.4	82.5	82.5	83.1
†Hispanic																	82.4	82.2	82.2	81.9	82.8
†Non-Hispanic																	77.9	77.2	76.2	76.4	75.9
Diabetes	72.9	72.7	72.5	72.3	72.6	72.1	73.4	73.4	74.6	75.4	75.8	76.1	76.6	78.6	78.0	77.9	78.0	77.4	76.6	77.2	77.1
Hypertension	82.0	81.1	79.7	77.5	77.1	77.6	76.6	74.9	74.7	75.6	76.8	75.7	76.0	76.7	76.5	77.6	77.4	76.2	75.6	75.4	75.5
Glomerulonephritis	90.1	88.5	87.7	86.8	86.6	86.5	85.0	84.9	85.1	85.0	85.7	84.4	86.2	87.2	85.5	86.4	87.1	86.5	86.9	86.4	86.4
Other cause	79.1	81.0	82.2	77.3	78.1	76.4	78.2	77.5	77.7	77.6	78.9	78.0	77.7	76.9	78.6	77.2	76.0	76.2	74.8	74.4	73.4
All	80.0	80.6	80.2	77.7	77.7	77.0	77.3	76.5	76.8	77.1	78.0	77.3	77.7	78.5	78.4	78.5	78.4	77.7	76.9	77.0	76.7
<b>ADJUSTED</b>																					
0-19	91.9	90.6	89.9	90.0	88.1	86.2	91.3	93.0	89.0	91.8	90.4	86.9	89.6	88.7	92.7	91.9	92.2	90.2	89.6	93.3	89.1
20-44	86.8	88.3	88.0	88.4	87.5	87.2	87.9	87.3	88.4	87.8	89.1	88.0	88.7	88.2	89.3	89.2	90.3	91.1	90.5	90.9	90.9
45-64	79.6	79.8	80.5	79.4	79.2	79.3	80.0	80.1	80.6	81.4	82.4	82.4	83.5	84.2	84.7	84.7	85.2	85.7	84.8	85.6	85.4
65-74	69.3	70.1	71.7	68.9	69.8	68.9	70.2	70.3	70.7	71.6	73.2	72.9	73.4	75.1	74.4	75.3	75.7	75.0	74.7	75.0	75.1
75+	59.9	61.6	61.5	58.4	60.6	61.8	61.9	59.0	59.7	62.1	63.1	63.1	62.6	63.9	64.8	64.3	64.6	63.7	62.9	63.1	63.1
Male	73.1	74.2	74.3	72.4	72.6	72.5	73.0	72.9	73.0	74.4	75.7	75.6	76.0	77.5	77.6	77.7	78.4	78.4	77.8	78.6	78.3
Female	74.3	74.9	75.9	74.3	74.8	74.5	75.9	74.8	76.0	76.3	77.4	77.0	77.7	78.1	78.6	79.0	79.1	78.8	78.1	78.1	78.3
White	71.7	72.4	72.7	70.7	70.5	70.9	71.5	70.8	71.7	72.9	74.0	73.7	74.4	75.5	76.1	76.4	77.0	76.4	76.1	76.6	76.6
Black	77.7	78.3	79.0	77.9	79.1	77.8	78.9	79.3	79.1	79.0	80.6	80.2	80.8	81.2	81.0	81.6	82.0	80.5	80.6	80.4	80.4
Other race	73.7	73.9	77.4	75.3	75.2	76.0	78.9	75.5	78.4	81.8	82.7	84.4	82.9	85.3	83.7	83.7	81.9	83.6	82.6	83.1	83.7
Diabetes	67.3	67.2	67.7	67.9	68.6	68.3	70.2	70.3	72.0	73.2	73.9	74.5	75.1	77.3	77.1	77.0	77.4	77.2	76.4	77.3	77.4
Hypertension	78.7	78.5	78.0	76.5	76.2	77.5	77.2	75.9	75.9	77.1	78.6	77.8	78.0	78.9	79.1	80.0	80.2	79.6	79.1	79.2	79.3
Glomerulonephritis	85.1	83.8	82.9	82.3	82.5	83.0	81.4	81.6	81.6	82.1	82.9	81.8	83.6	84.7	83.6	84.3	85.6	84.9	85.4	85.3	85.0
Other cause	75.6	76.8	78.7	75.4	75.7	74.1	76.1	75.6	75.6	75.7	77.1	76.4	76.5	76.4	77.2	76.1	75.5	76.1	74.9	74.7	73.8
All	73.7	74.5	75.1	73.3	73.6	73.5	74.3	73.8	74.4	75.3	76.5	76.3	76.8	77.8	78.1	78.3	78.8	78.6	78.0	78.3	78.3

**Standard Errors**

	<b>1980</b>	<b>1981</b>	<b>1982</b>	<b>1983</b>	<b>1984</b>	<b>1985</b>	<b>1986</b>	<b>1987</b>	<b>1988</b>	<b>1989</b>	<b>1990</b>	<b>1991</b>	<b>1992</b>	<b>1993</b>	<b>1994</b>	<b>1995</b>	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>
0-4	5.2	4.7	4.4	4.3	4.8	4.2	2.7	2.1	4.6	4.1	4.5	4.4	3.8	4.2	3.5	3.8	3.1	4.2	4.1	3.8	3.8
5-9	4.8	3.0	3.3	1.9	4.9	4.8	0.0	0.0	0.0	0.0	3.0	3.4	4.1	2.6	0.0	1.6	3.5	2.9	0.0	2.2	1.9
10-14	1.8	1.1	1.5	1.4	1.7	1.4	1.3	1.2	2.0	2.5	1.9	1.5	2.2	2.5	0.9	1.2	1.5	2.2	1.3	2.0	2.0
15-19	1.2	1.3	1.5	1.4	1.2	1.7	1.6	1.4	1.2	0.8	1.1	1.3	1.0	1.1	1.3	0.9	1.0	0.9	1.4	0.8	1.2
20-29	1.0	0.8	0.8	0.8	0.8	0.8	0.7	0.8	0.7	0.7	0.7	0.7	0.6	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.6
30-39	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
40-49	0.7	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
50-59	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3
60-64	1.0	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
65-69	1.0	1.0	0.9	0.8	0.8	0.8	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4
70-79	1.0	1.0	0.9	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3
80+	2.6	2.6	2.1	1.7	1.6	1.5	1.3	1.2	1.1	1.0	0.9	0.9	0.8	0.8	0.7	0.7	0.6	0.6	0.6	0.5	0.5
Male	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Female	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
White	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Black	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Other race	1.7	1.6	1.6	1.4	1.3	1.2	1.1	1.1	1.0	1.0	0.9	0.8	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6
†Hispanic																					
†Non-Hispanic																	0.5	0.5	0.4	0.4	0.4
Diabetes	1.0	0.8	0.7	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2
Hypertension	0.8	0.7	0.6	0.6	0.5	0.5															

**Table I.13**  
**Two-year Survival Probabilities: Incident Dialysis Patients**  
*censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	72.0	88.1	85.6	77.2	81.5	78.6	85.9	85.6	70.0	79.6	79.6	78.4	87.2	85.7	81.8	80.0	85.0	77.8	82.2	88.2
5-9	86.7	95.6	90.1	88.7	83.2	88.5	80.8	100.0	100.0	95.5	88.3	95.1	94.1	92.7	97.0	98.4	90.7	95.8	93.6	94.2
10-14	95.0	94.2	92.7	95.9	90.1	96.0	94.5	98.8	93.6	94.9	88.1	95.9	90.9	89.5	96.1	94.3	92.7	91.9	96.6	95.9
15-19	94.2	89.8	91.7	89.4	92.5	91.4	87.9	93.3	94.2	95.4	94.4	91.8	94.6	92.2	93.7	95.1	90.8	92.2	91.0	92.4
20-29	81.6	83.9	84.3	82.5	83.7	79.6	83.8	80.8	84.5	84.7	83.8	84.1	86.0	86.1	87.4	85.6	88.3	89.6	90.7	89.8
30-39	78.1	79.3	77.3	79.3	75.4	74.5	75.6	76.0	78.6	77.9	78.5	77.6	78.8	79.9	79.4	80.8	81.7	83.3	82.2	83.8
40-49	75.8	75.2	75.2	74.5	74.2	74.5	73.5	73.7	75.5	75.2	78.1	74.3	76.7	76.8	77.9	78.9	78.6	79.5	79.4	79.3
50-59	69.9	69.7	70.1	67.3	66.4	66.1	66.3	66.3	67.4	68.5	68.9	69.1	70.1	71.2	72.4	72.0	72.1	72.6	71.6	72.9
60-64	63.2	60.5	60.3	61.0	58.1	57.8	59.3	58.4	59.1	60.2	60.4	61.8	62.4	64.1	65.0	63.6	65.8	65.7	64.1	66.0
65-69	54.7	55.9	55.0	52.1	55.1	52.9	53.8	55.2	55.8	55.7	56.2	56.6	57.7	59.6	58.6	59.4	60.2	58.6	58.7	59.0
70-79	46.6	48.6	48.8	44.0	46.3	46.9	46.4	45.4	46.3	47.6	47.8	48.1	49.0	50.1	50.2	50.6	51.3	49.4	50.5	50.5
80+	30.5	33.7	37.3	30.3	36.7	35.5	35.0	33.1	33.1	37.5	36.6	36.1	36.6	37.4	38.3	38.1	37.9	36.8	36.8	37.0
Male	64.2	65.4	64.2	60.2	60.6	58.4	59.1	58.4	59.5	60.4	60.5	60.2	60.9	62.4	62.2	62.6	62.4	61.4	61.5	61.9
Female	66.5	66.4	65.8	61.9	62.3	62.0	61.1	60.4	61.4	61.4	61.4	60.6	61.7	61.7	62.2	62.1	62.2	60.7	60.4	60.3
White	62.9	63.5	61.9	57.7	57.3	56.2	55.5	55.1	55.4	56.0	56.0	55.3	56.3	56.7	57.2	57.2	57.3	55.8	56.3	56.8
Black	68.8	70.2	70.7	67.2	69.1	67.5	68.2	67.2	69.3	68.9	69.4	68.5	69.6	70.4	70.3	70.4	70.5	70.2	68.9	68.8
Other race	67.5	64.5	69.7	63.6	65.5	62.0	65.3	63.2	65.9	69.9	69.5	73.7	71.4	72.9	71.0	70.2	68.2	69.4	68.9	70.0
†Hispanic																	67.6	67.5	68.1	68.5
†Non-Hispanic																	61.6	60.3	60.1	60.2
Diabetes	53.8	52.5	51.9	53.4	51.0	51.2	52.1	52.7	54.6	56.3	55.9	56.8	57.8	60.0	59.4	59.6	59.9	59.1	59.0	60.0
Hypertension	67.6	66.3	64.9	61.1	62.4	61.1	59.9	58.0	58.9	59.8	59.7	58.9	60.0	60.6	60.8	61.8	61.7	59.8	59.7	59.6
Glomerulonephritis	79.7	76.7	76.1	74.3	75.0	72.4	71.3	71.4	73.2	71.8	73.1	71.4	73.9	75.4	73.6	74.9	75.2	74.2	75.8	75.1
Other cause	64.4	67.8	68.7	60.5	62.9	62.0	63.4	62.9	63.0	63.6	64.7	63.4	63.4	61.6	64.3	62.7	62.1	61.6	60.9	60.4
All	65.3	65.9	64.9	61.0	61.4	60.1	60.0	59.4	60.4	60.9	61.0	60.4	61.3	62.1	62.2	62.3	62.3	61.1	61.0	61.2
ADJUSTED																				
0-19	87.0	83.8	83.8	80.3	80.8	81.8	78.7	89.3	83.3	87.5	82.7	82.7	86.1	83.1	87.3	86.7	82.6	81.8	83.8	86.6
20-44	74.6	77.3	76.8	76.8	75.2	74.0	75.4	75.2	77.7	77.3	78.5	76.7	78.3	78.3	79.4	79.7	81.0	82.6	82.1	82.7
45-64	65.0	64.0	65.1	64.0	62.7	62.7	63.7	63.3	64.6	66.2	67.1	67.4	68.5	69.9	71.0	70.7	71.7	72.3	71.4	72.7
65-74	49.3	51.7	52.8	48.1	51.2	50.1	50.7	51.5	52.6	53.2	53.6	54.1	55.5	56.3	56.2	57.5	58.0	56.6	57.3	57.7
75+	37.4	40.6	39.3	35.2	39.8	40.4	39.7	37.6	38.2	41.6	41.4	41.4	41.6	42.7	43.6	43.0	43.9	42.4	43.0	43.4
Male	55.1	56.6	56.6	54.0	54.7	53.6	55.0	54.4	55.8	57.6	58.1	58.3	59.3	61.0	61.4	61.8	62.6	62.4	62.6	63.6
Female	57.9	58.2	59.3	56.7	57.8	58.2	58.1	58.1	59.2	60.2	60.7	60.5	61.9	61.9	63.0	63.1	63.9	63.2	63.0	63.3
White	53.4	54.6	54.4	51.8	52.2	52.2	52.4	52.6	53.4	55.3	55.6	55.7	56.9	57.6	58.9	59.1	60.1	59.4	60.0	60.8
Black	62.2	62.4	63.4	61.2	63.0	61.8	63.3	62.4	64.4	64.3	65.5	64.9	66.1	67.4	67.3	67.5	68.2	68.1	66.8	66.8
Other race	58.2	56.1	60.8	56.2	58.3	57.0	60.7	59.4	62.3	67.3	67.1	71.8	69.9	71.9	69.9	69.6	68.1	70.2	69.5	71.2
Diabetes	47.0	46.0	46.2	48.2	46.4	46.9	48.2	49.1	51.5	53.6	53.6	54.9	56.0	58.3	58.3	58.5	59.2	59.0	58.9	60.3
Hypertension	63.0	62.9	62.9	59.9	61.6	61.5	61.2	59.9	61.0	62.3	62.8	62.4	63.2	64.1	64.8	65.7	66.1	64.9	65.1	65.2
Glomerulonephritis	71.2	69.4	69.0	67.7	69.1	67.5	66.6	66.9	68.3	67.9	69.2	67.9	70.3	71.6	71.0	71.9	73.0	72.0	73.6	73.5
Other cause	59.8	62.0	63.7	58.2	60.1	59.3	61.1	60.7	60.6	61.6	62.6	61.5	62.2	61.5	62.7	61.5	61.7	61.7	61.3	61.1
All	56.4	57.4	57.8	55.3	56.2	55.8	56.4	56.2	57.4	58.8	59.3	59.4	60.5	61.4	62.1	62.4	63.2	62.7	62.8	63.5

**Standard Errors**

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	13.6	5.5	5.6	7.3	5.2	5.6	5.0	6.3	6.2	5.4	5.7	4.6	3.8	4.2	5.1	4.8	4.2	5.5	5.4	4.2
5-9	6.3	3.0	5.9	6.4	6.9	4.8	8.5	0.0	0.0	4.3	5.2	3.4	4.1	4.2	2.9	1.6	4.5	2.9	4.3	3.4
10-14	2.5	2.6	3.0	2.5	3.5	2.4	3.1	1.2	3.4	2.5	3.8	2.1	3.0	3.3	2.2	2.5	2.7	2.8	2.0	2.0
15-19	1.5	1.9	1.9	2.2	2.1	2.1	2.5	1.7	1.6	1.4	1.5	1.8	1.4	1.8	1.6	1.4	1.8	2.0	1.8	1.8
20-29	1.4	1.2	1.2	1.2	1.1	1.3	1.1	1.2	1.0	1.0	1.0	1.0	0.9	0.9	0.8	0.9	0.8	0.8	0.7	0.8
30-39	1.1	1.0	1.0	1.0	1.0	1.0	0.9	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.7	0.6
40-49	1.0	1.0	0.9	0.9	0.9	0.9	0.8	0.8	0.7	0.7	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5
50-59	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4
60-64	1.1	1.1	1.0	0.9	0.9	0.8	0.8	0.8	0.8	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
65-69	1.1	1.1	1.0	0.9	0.9	0.8	0.8	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5
70-79	1.1	1.0	0.9	0.8	0.8	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
80+	2.4	2.4	2.1	1.6	1.6	1.4	1.3	1.2	1.1	1.0	0.9	0.8	0.8	0.8	0.7	0.7	0.6	0.6	0.6	0.5
Male	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Female	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
White	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2
Black	0.6	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
Other race	2.1	2.0	2.1	1.8	1.6	1.6	1.4	1.3	1.2	1.3	1.2	1.0	1.0	0.9	0.9	0.7	0.7	0.8	0.7	0.7
†Hispanic																				
†Non-Hispanic																	0.6	0.6	0.5	0.5
Diabetes	1.2	0.9	0.8	0.7	0.7	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
Hypertension	1.0	0.8	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Glomerulonephritis	1.0	0.9	0.8	0.8	0.8	0.8	0.8	0.8	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
Other cause	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.4	0.5	0.4	0.5	0.5	0.5	0.4
All	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.  
 The age of the incident patient is determined as of the date of ESRD initiation.  
 Patients of unknown age, gender, race, or primary diagnosis are excluded.  
 Includes U.S. & territories; no unknown or foreign states.  
 †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

**Table I.14**  
**Five-year Survival Probabilities: Incident Dialysis Patients**  
*censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996
0-4	72.0	72.5	85.6	77.2	64.4	64.8	85.9	80.6	66.3	74.6	69.4	68.1	69.2	66.8	69.3	68.1	73.2
5-9	86.7	77.2	69.5	78.8	83.2	57.5	71.8	81.8	90.9	84.8	77.2	95.1	77.2	77.9	85.8	87.5	86.4
10-14	78.4	75.2	83.8	92.8	86.7	96.0	78.1	82.1	76.6	87.1	79.3	78.8	79.3	78.5	78.8	84.4	82.7
15-19	87.8	80.4	77.6	84.8	83.9	69.7	74.9	82.1	75.7	79.0	84.6	83.4	85.1	78.6	80.1	84.5	82.6
20-29	72.7	66.8	67.5	62.8	61.3	58.5	65.3	61.4	67.3	63.7	66.5	66.7	68.5	69.9	71.7	72.1	73.0
30-39	58.9	58.2	52.7	54.6	53.0	50.3	50.7	48.6	54.6	55.0	54.4	53.7	55.6	57.7	56.8	59.6	60.6
40-49	50.8	50.2	49.3	46.0	47.7	46.6	46.7	46.7	48.3	45.8	47.8	47.1	48.3	49.5	50.2	52.6	51.3
50-59	39.3	39.5	38.9	36.3	34.8	33.6	34.9	35.9	35.0	35.3	34.8	37.0	36.7	38.9	39.0	39.5	39.2
60-64	30.6	30.1	28.1	28.1	25.5	25.8	26.7	25.6	27.3	27.0	27.3	27.6	28.3	29.2	30.2	29.1	30.7
65-69	23.0	24.4	23.8	20.6	22.1	22.2	21.9	22.6	22.4	22.3	22.5	21.6	23.6	23.7	24.6	24.0	24.8
70-79	15.8	15.8	17.0	13.5	15.3	15.5	14.8	15.2	15.4	16.0	15.6	15.9	15.8	16.7	16.7	17.1	17.6
80+	7.1	5.9	5.9	6.4	7.4	8.2	7.4	7.8	6.7	8.9	8.6	7.7	7.5	8.0	8.2	8.7	8.6
Male	35.4	34.4	33.0	28.9	28.5	27.0	27.6	27.6	28.2	28.6	28.2	28.2	28.3	29.6	29.6	30.9	30.2
Female	37.6	38.3	35.6	31.6	31.5	30.7	30.0	29.4	30.0	28.9	28.9	28.3	29.0	29.1	29.4	29.2	29.1
White	34.2	32.4	30.6	26.2	25.6	24.5	23.7	23.4	23.0	22.9	22.4	22.1	22.5	23.1	23.4	23.2	23.4
Black	40.2	43.0	40.9	36.8	38.0	36.8	37.7	37.1	39.4	38.2	38.9	38.3	38.8	39.1	39.4	41.2	40.0
Other race	32.4	33.2	38.5	36.1	32.8	29.7	34.2	34.7	36.1	38.8	37.1	38.9	38.1	39.3	39.2	37.2	36.3
†Hispanic																	35.4
†Non-Hispanic																	29.0
Diabetes	22.8	21.0	19.1	19.4	18.2	17.6	19.7	19.4	20.9	20.9	20.8	21.8	22.5	24.1	24.0	24.0	24.4
Hypertension	39.4	35.7	33.9	31.1	30.5	30.4	28.7	27.5	28.7	29.1	29.1	27.7	28.6	29.0	28.7	30.7	30.3
Glomerulonephritis	53.4	49.6	48.1	44.4	43.8	39.6	40.1	40.6	42.9	41.5	42.1	42.4	43.7	45.5	44.4	46.2	45.8
Other cause	35.7	39.1	39.1	31.1	33.8	33.7	34.1	34.8	33.7	34.5	34.3	34.3	33.6	32.1	35.3	34.9	34.1
All	36.4	36.3	34.2	30.1	29.9	28.8	28.8	28.4	29.1	28.7	28.5	28.2	28.7	29.4	29.5	30.1	29.7
<b>ADJUSTED</b>																	
0-19	74.3	64.3	64.8	73.5	68.9	55.4	61.8	70.5	60.8	67.8	67.7	67.9	68.8	62.6	65.9	70.0	69.5
20-44	54.5	54.1	51.8	50.1	50.5	47.6	51.0	49.2	52.7	52.3	53.4	52.2	53.8	54.8	55.8	57.3	57.8
45-64	32.9	32.9	33.3	31.6	30.3	30.1	31.5	31.5	32.4	32.8	33.2	35.1	35.2	37.0	37.8	38.3	39.1
65-74	18.0	19.5	20.3	16.8	18.7	19.1	18.5	19.6	20.0	20.3	20.5	20.0	21.6	21.5	22.5	22.6	23.5
75+	10.1	9.9	10.3	8.3	10.1	10.7	10.6	10.3	9.7	11.7	10.7	11.3	10.3	11.1	11.3	12.0	12.4
Male	26.6	26.2	26.4	24.0	24.4	24.3	25.3	25.3	25.9	27.4	27.1	27.9	28.0	29.4	29.9	31.0	31.6
Female	28.7	29.9	29.6	27.5	28.4	28.3	28.5	28.7	29.2	29.1	29.6	29.8	30.8	30.8	31.8	31.8	32.6
White	25.3	24.4	24.6	22.3	22.8	22.9	23.0	23.2	23.4	24.5	24.2	24.7	25.5	26.2	27.1	27.3	28.5
Black	32.3	33.9	32.7	30.4	31.7	31.1	32.7	32.6	34.2	33.5	34.7	35.0	36.0	36.3	36.3	37.9	37.5
Other race	24.7	26.4	29.6	29.6	27.2	27.2	31.1	32.1	33.4	37.6	35.6	38.8	38.1	39.6	39.2	37.7	37.5
Diabetes	18.4	16.9	16.2	16.7	16.1	16.1	17.9	17.9	19.4	19.9	20.0	21.2	22.0	23.6	24.0	24.0	24.8
Hypertension	35.1	33.0	33.3	31.3	31.2	32.3	31.7	31.5	32.3	33.2	33.7	32.9	33.4	34.1	34.4	35.9	36.3
Glomerulonephritis	42.5	41.1	40.4	38.0	38.5	35.6	36.6	36.9	38.7	38.7	38.5	39.9	40.3	41.7	42.2	42.8	43.7
Other cause	31.4	33.4	34.5	29.7	32.3	32.2	33.0	33.6	32.4	33.7	33.2	33.5	33.6	33.1	34.6	34.1	34.5
All	27.6	27.9	27.9	25.6	26.2	26.1	26.8	26.8	27.4	28.2	28.2	28.7	29.3	30.1	30.8	31.3	32.0

**Standard Errors**

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996
0-4	13.6	11.0	5.6	7.3	9.5	9.6	5.0	7.6	6.8	6.9	8.4	7.8	8.8	8.0	7.9	7.6	6.5
5-9	6.3	11.6	12.9	10.4	6.9	14.0	11.0	11.1	8.3	10.2	8.4	3.4	11.3	10.0	6.5	9.8	5.9
10-14	6.4	6.4	5.6	3.9	4.7	2.4	8.9	7.6	8.1	5.6	6.1	6.9	6.2	5.9	5.9	5.3	6.0
15-19	2.5	3.0	4.3	2.9	3.9	4.8	4.1	3.6	4.2	3.5	3.2	3.0	2.9	3.4	3.5	2.7	2.8
20-29	1.7	1.9	1.8	1.9	1.9	2.0	1.7	1.8	1.6	1.6	1.5	1.5	1.4	1.4	1.4	1.3	1.3
30-39	1.5	1.4	1.4	1.4	1.4	1.3	1.3	1.3	1.1	1.1	1.1	1.0	1.0	1.0	0.9	0.9	0.9
40-49	1.3	1.2	1.2	1.1	1.2	1.1	1.1	1.0	1.0	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.7
50-59	0.9	0.8	0.8	0.8	0.8	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.5	0.5	0.5
60-64	1.1	1.0	0.9	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.6
65-69	1.0	1.0	0.9	0.7	0.8	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5
70-79	0.8	0.8	0.7	0.5	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
80+	1.3	1.2	1.0	0.8	0.9	0.8	0.7	0.7	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4
Male	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Female	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
White	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2
Black	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Other race	2.2	2.1	2.3	1.9	1.7	1.6	1.5	1.4	1.3	1.4	1.3	1.2	1.1	1.1	1.0	0.8	0.8
†Hispanic																	0.6
†Non-Hispanic																	0.2
Diabetes	1.0	0.8	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
Hypertension	1.1	0.8	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Glomerulonephritis	1.4	1.2	1.1	1.0	1.0	1.0	1.0	0.9	0.9	0.9	0.8	0.8	0.8	0.8	0.7	0.7	0.7
Other cause	0.6	0.6	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5
All	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.  
 The age of the incident patient is determined as of the date of ESRD initiation.  
 Patients of unknown age, gender, race, or primary diagnosis are excluded.  
 Includes U.S. & territories; no unknown or foreign states.  
 †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

**Table I.15**  
**Ten-year Survival Probabilities: Incident Dialysis Patients**  
*censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	72.0	72.5	64.2	57.9	53.7	25.9	85.9	80.6	46.4	74.6	47.6	59.6
5-9	86.7	52.9	52.1	78.8	83.2	38.3	71.8	81.8	90.9	70.7	57.9	50.7
10-14	55.9	50.0	61.8	76.9	69.5	86.4	68.4	75.8	58.1	54.8	60.5	70.9
15-19	77.0	61.8	64.3	70.5	61.4	53.1	54.5	59.1	61.8	65.9	63.3	66.4
20-29	52.7	46.0	46.9	42.5	41.9	41.2	42.7	40.4	45.0	40.7	44.8	42.8
30-39	37.8	33.9	30.3	32.3	31.3	29.4	28.4	27.5	28.8	30.3	30.9	30.4
40-49	23.9	23.1	22.3	21.3	23.0	20.6	20.4	20.9	22.1	18.7	20.0	19.6
50-59	12.3	13.6	13.4	11.3	10.9	11.6	10.5	11.1	10.2	10.3	10.2	10.8
60-64	7.3	7.3	5.5	7.0	6.6	7.1	6.7	5.8	6.5	5.4	5.4	5.4
65-69	4.5	4.8	3.7	4.6	4.9	5.7	4.6	4.1	4.2	4.0	4.4	3.9
70-79	2.4	2.0	2.8	2.1	2.8	2.7	2.2	2.4	2.2	2.0	1.9	1.7
80+	1.4	0.5	1.3	0.2	1.1	0.8	0.5	0.8	0.4	0.6	0.3	0.6
Male	12.7	11.8	10.7	9.7	9.9	9.4	9.2	8.9	8.8	8.3	8.7	8.1
Female	14.8	14.7	12.5	11.1	10.9	10.5	9.2	8.8	9.3	8.3	8.0	7.9
White	12.1	10.7	9.9	8.3	8.3	7.6	6.8	6.6	6.0	5.4	5.5	5.2
Black	16.2	17.1	14.8	13.7	13.9	14.2	13.2	12.6	14.2	13.1	13.1	12.7
Other race	11.3	12.9	12.9	13.8	12.9	11.4	13.4	12.4	12.8	12.0	12.6	11.5
Diabetes	5.6	4.7	4.4	4.1	4.0	4.0	3.8	4.1	4.3	3.8	3.9	3.7
Hypertension	12.8	12.0	10.1	10.4	10.3	9.8	9.0	7.8	8.5	8.6	8.0	8.0
Glomerulonephritis	26.4	21.4	19.2	18.3	18.5	17.1	16.9	16.5	17.2	15.2	17.3	16.1
Other cause	13.7	15.3	15.0	11.8	12.7	13.2	12.4	12.8	12.5	12.3	12.8	12.9
All	13.7	13.2	11.6	10.4	10.3	9.9	9.2	8.8	9.0	8.3	8.4	8.0
<b>ADJUSTED</b>												
0-19	56.2	43.2	43.4	53.4	44.6	36.3	40.7	48.7	43.9	49.6	43.5	47.0
20-44	31.7	29.1	27.2	27.1	27.8	26.3	27.0	26.0	27.1	27.1	28.2	27.4
45-64	9.0	9.5	9.7	9.0	9.0	9.4	9.3	9.3	9.5	9.0	9.4	9.9
65-74	3.0	3.2	3.1	3.2	3.8	4.3	3.5	3.3	3.3	3.3	3.5	3.2
75+	1.2	1.1	1.5	0.7	1.6	1.3	1.1	1.4	1.1	1.0	0.7	1.0
Male	8.8	8.5	8.7	8.2	8.8	9.4	9.2	8.9	8.6	8.7	9.1	9.0
Female	10.4	10.8	10.6	10.0	10.6	10.6	9.8	10.0	10.4	9.9	9.9	10.2
White	8.4	8.0	8.2	7.6	8.3	8.5	8.1	8.0	7.6	7.7	7.9	8.0
Black	11.4	11.8	10.9	10.5	11.0	11.5	10.8	10.9	11.8	11.0	11.4	11.3
Other race	8.2	10.0	11.0	11.2	11.2	11.5	12.7	12.8	12.9	13.6	13.0	13.5
Diabetes	4.4	3.9	4.0	3.8	4.0	4.3	3.9	4.2	4.3	3.9	4.2	4.2
Hypertension	11.9	12.0	11.6	11.9	12.1	12.5	12.1	11.6	11.6	11.8	11.6	11.7
Glomerulonephritis	18.3	16.6	15.8	15.2	16.5	16.2	16.0	15.3	15.8	14.8	15.7	15.6
Other cause	12.2	12.9	13.4	11.9	13.1	13.6	12.9	13.1	12.7	12.9	13.0	13.5
All	9.5	9.5	9.5	9.0	9.6	9.9	9.4	9.4	9.4	9.2	9.4	9.5

**Standard Errors**

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	13.6	11.0	16.6	15.5	12.0	12.6	5.0	7.6	10.2	6.9	13.0	10.1
5-9	6.3	15.2	16.2	10.4	6.9	15.8	11.0	11.1	8.3	14.5	15.8	19.8
10-14	8.4	10.8	9.3	8.7	9.4	8.9	11.6	9.2	12.6	12.8	10.2	9.4
15-19	4.2	4.6	6.2	5.0	7.0	6.3	5.8	5.6	5.2	4.8	5.5	4.9
20-29	2.4	2.4	2.4	2.3	2.2	2.3	2.1	2.1	2.1	2.0	1.9	1.9
30-39	1.7	1.6	1.5	1.5	1.5	1.4	1.3	1.3	1.2	1.1	1.1	1.1
40-49	1.2	1.1	1.1	1.0	1.1	1.0	1.0	0.9	0.9	0.8	0.8	0.7
50-59	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4
60-64	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3
65-69	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.2
70-79	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.1	0.1
80+	0.6	0.3	0.5	0.1	0.3	0.3	0.2	0.2	0.1	0.2	0.1	0.1
Male	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2
Female	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.2
White	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Black	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3
Other race	1.6	1.6	1.8	1.5	1.3	1.2	1.2	1.0	1.0	1.0	1.0	0.9
Diabetes	0.6	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
Hypertension	0.8	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3
Glomerulonephritis	1.4	1.1	0.9	0.9	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.7
Other cause	0.4	0.5	0.6	0.4	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4
All	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.  
The age of the incident patient is determined as of the date of ESRD initiation.  
Patients of unknown age, gender, race, or primary diagnosis are excluded.  
Includes U.S. & territories; no unknown or foreign states.